Cargando…
P-loop Conformation Governed Crizotinib Resistance in G2032R-Mutated ROS1 Tyrosine Kinase: Clues from Free Energy Landscape
Tyrosine kinases are regarded as excellent targets for chemical drug therapy of carcinomas. However, under strong purifying selection, drug resistance usually occurs in the cancer cells within a short term. Many cases of drug resistance have been found to be associated with secondary mutations in dr...
Autores principales: | Sun, Huiyong, Li, Youyong, Tian, Sheng, Wang, Junmei, Hou, Tingjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102447/ https://www.ncbi.nlm.nih.gov/pubmed/25033171 http://dx.doi.org/10.1371/journal.pcbi.1003729 |
Ejemplares similares
-
Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib
por: Bielec, Bjoern, et al.
Publicado: (2020) -
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
por: Katayama, Ryohei, et al.
Publicado: (2019) -
Combating Drug-Resistant Mutants of Anaplastic Lymphoma
Kinase with Potent and Selective Type-I(1/2) Inhibitors
by Stabilizing Unique DFG-Shifted Loop Conformation
por: Pan, Peichen, et al.
Publicado: (2017) -
Evolutionary divergence in the conformational landscapes of tyrosine vs serine/threonine kinases
por: Gizzio, Joan, et al.
Publicado: (2022) -
Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy
por: Jóri, Balázs, et al.
Publicado: (2022)